| P2093 | author name string | Barbara J Seaworth | |
| P2860 | cites work | Fluoroquinolone toxicity profiles: a review focusing on newer agents | Q28138100 |
| | A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis | Q28139874 |
| | Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project | Q28145755 |
| | Treatment of multidrug-resistant tuberculosis | Q28261482 |
| | The emergence of drug-resistant tuberculosis in New York City | Q28262856 |
| | Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin | Q28265640 |
| | Activity of amoxicillin/clavulanate in patients with tuberculosis | Q28269050 |
| | In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis | Q28329600 |
| | Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis | Q28333284 |
| | High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection | Q28343757 |
| | Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance | Q28369156 |
| | Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains | Q28369163 |
| | In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis | Q28378679 |
| | In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis | Q28379137 |
| | Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis | Q33497667 |
| | Treatment and prevention of multidrug-resistant tuberculosis | Q33768742 |
| | Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus". | Q33791822 |
| | The fluoroquinolones | Q33986571 |
| | USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results | Q34183812 |
| | Tuberculosis control in the 21st century | Q34213674 |
| | Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention | Q34340511 |
| | Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family | Q36798677 |
| | Infectious disease morbidity in the US region bordering Mexico, 1990-1998. | Q38473142 |
| | Aminoglycoside-induced hearing loss in humans | Q38676819 |
| | Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico | Q39224709 |
| | Drug-resistant tuberculosis in an urban population including patients at risk for human immunodeficiency virus infection | Q39234663 |
| | Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis | Q39418630 |
| | A study of tuberculosis among foreign-born Hispanic persons in the U.S. States bordering Mexico | Q39488153 |
| | Predictors and outcome of multidrug-resistant tuberculosis | Q40678189 |
| | Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report | Q40700812 |
| | Treatment and implications of multidrug-resistant tuberculosis for the 21st century | Q40801214 |
| | Lichenoid drug eruptions | Q40827470 |
| | Seizures associated with ofloxacin therapy | Q41072188 |
| | The clinical use of fluoroquinolones for the treatment of mycobacterial diseases | Q41663890 |
| | Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol | Q42657080 |
| | The treatment of multidrug-resistant tuberculosis in Turkey | Q43681408 |
| | Uveitis associated with rifabutin prophylaxis | Q43874569 |
| | The global threat of drug-resistant tuberculosis | Q44397097 |
| | Transmission of a multidrug-resistant Mycobacterium tuberculosis strain resembling "strain W" among noninstitutionalized, human immunodeficiency virus-seronegative patients. | Q45746865 |
| | Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease | Q45765934 |
| | Tuberculosis among foreign-born persons in the United States, 1993-1998. | Q46255853 |
| | Classification of drug-resistant tuberculosis in an epidemic area | Q46669080 |
| | Transmission of multidrug-resistant tuberculosis. | Q46791874 |
| | Pharmacodynamics of fluoroquinolones. | Q52994131 |
| | Quinolones and multidrug-resistant tuberculosis. | Q54082130 |
| | Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis. | Q54118810 |
| | Initial drug regimens for the treatment of tuberculosis: evaluation of physician prescribing practices in New Jersey, 1994 to 1995. | Q54134617 |
| | Outcome of MDR-TB patients, 1983-1993. Prolonged survival with appropriate therapy. | Q54154651 |
| | Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. | Q54171121 |
| | Emergence of fluoroquinolone-resistant tuberculosis in New York City. | Q54172782 |
| | The third epidemic--multidrug-resistant tuberculosis. | Q54217932 |
| | Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis | Q54256768 |
| | Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. | Q54329917 |
| | Exogenous reinfection with tuberculosis in a shelter for the homeless. | Q54418181 |
| | Treatment of tuberculosis by the nonpulmonary physician | Q54596878 |
| | Paradox of the global emergency of tuberculosis | Q56410400 |
| | Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis | Q56485916 |
| | A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes | Q57109529 |
| | First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons | Q61680488 |
| | Trends in drug-resistant tuberculosis in the United States, 1993-1996 | Q64133623 |
| | Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin | Q64133815 |
| | Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients | Q64135141 |
| | Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month | Q67985481 |
| | Rifabutin-induced ageusia | Q70460175 |
| | Cycloserine-induced lichenoid drug eruption | Q70783586 |
| | Unusual pigmentation in patients with AIDS who are receiving rifabutin for bacteremia due to Mycobacterium avium/Mycobacterium intracellulare complex | Q71373577 |
| | Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? | Q72160134 |
| | Current role of surgery in Mycobacterium tuberculosis | Q72289983 |
| | Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis | Q72319834 |
| | Drug-resistant tuberculosis: issues in epidemiology and challenges for public health | Q72498267 |
| | Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group | Q72498286 |
| | Drug development for tuberculosis: the missing ingredient | Q73523992 |
| | The use of high-dose isomazid in intermittent regime TB treatment--some preliminary findings | Q73865088 |
| | Beta-lactam drugs and tuberculosis | Q74492570 |
| | Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia | Q78134940 |
| | Tuberculosis, Russia, and the Holy Grail | Q78165478 |
| | Levofloxacin-induced bilateral Achilles tendonitis | Q78192076 |
| P433 | issue | 1 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 73-105 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Infectious Disease Clinics of North America | Q15754797 |
| P1476 | title | Multidrug-resistant tuberculosis | |
| P478 | volume | 16 | |